A study of sacituzumab govitecan for advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a drug called sacituzumab govitecan for people with advanced esophageal squamous cell carcinoma that has already been treated with chemotherapy and immunotherapy. The drug targets a protein called Trop-2 on cancer cells to try to stop tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older with advanced esophageal squamous cell carcinoma that has spread or come back after platinum chemotherapy and an anti-PD-1/PD-L1 drug.
- You have at least one tumor that can be measured on scans (not in an area previously treated with radiation unless it has grown since).
- You are able to carry out daily activities with little help (ECOG score 0 or 1).
- You have adequate blood cell counts, liver function, and kidney function, and are not taking blood thinners or growth factors within 2 weeks of starting the drug.
- You have archived tumor tissue available for testing (a fresh biopsy is optional).
- You have no active hepatitis B or C, HIV, brain metastases, or inflammatory bowel disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs for advanced esophageal cancer that has grown despite earlier treatment. The goal is to see if this combination can help shrink tumors and slow the disease.
This study tests a new combination of two drugs (sacituzumab tirumotecan and another drug) for people with advanced esophageal cancer. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
This trial tests a drug called sacituzumab govitecan for people with advanced thymic cancer (thymoma or thymic carcinoma) that has not responded to previous treatments. The goal is to see if the drug can shrink or slow the growth of the cancer.
This trial tests a new drug called sacituzumab govitecan against the usual treatments for people with extensive-stage small cell lung cancer that has gotten worse after initial chemotherapy. It aims to see if the new drug helps patients live longer or have better outcomes.
This study tests a drug called sacituzumab govitecan for people with metastatic colorectal cancer who have already tried several standard treatments. It may be an option if your cancer is not MSI-H or dMMR and you haven't had irinotecan recently.
This study tests a drug called sacituzumab govitecan (a targeted therapy that delivers chemotherapy directly to cancer cells) for people with mesothelioma that has already been treated with other therapies. The goal is to see if the drug can shrink tumors and help control the disease.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.